Ovarian cancer

Colombo, Nicoletta; Gorp, Toon Van; Parma, Gabriella; Amant, Frédéric; Gatta, Gemma; Sessa, Cristiana; Vergote, Ignace

doi:10.1016/j.critrevonc.2006.03.004

Cited by 200 publications

(172 citation statements)

References 140 publications

Supporting

Mentioning

160

Contrasting

Unclassified

Order By: Relevance

“…These studies suggest response rates similar to those achieved in other cancers, such as colorectal, lung, ovarian cancers (Schöffski 2002;Colombo et al, 2006;Goldberg et al, 2007;Vansteenkiste, 2007). However, we still lack of phase III trials comparing second-line chemotherapy vs best supportive care.…”

Section: Second-line Chemotherapy In Metastatic Gastric Cancer V Catamentioning

confidence: 98%

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?

et al. 2008

View full text Add to dashboard Cite

No established second-line chemotherapy is available for patients with advanced gastric cancer failing to respond or progressing to first-line chemotherapy. However, 20 -40% of these patients commonly receive second-line chemotherapy. We evaluated the influence of clinico-pathologic factors on the survival of 175 advanced gastric cancer patients, who received second-line chemotherapy at three oncology departments. Univariate and multivariate analyses found five factors which were independently associated with poor overall survival: performance status 2 (hazard ratio (HR), 1.79; 95% CI, 1.16 -2.77; P ¼ 0.008), haemoglobin p11.5 g l À1 (HR, 1.48; 95% CI, 1.06 -2.05; P ¼ 0.019), CEA level 450 ng ml À1 (HR, 1.86; 95% CI, 1.21 -2.88; P ¼ 0.004), the presence of greater than or equal to three metastatic sites of disease (HR, 1.72; 95% CI, 1.16 -2.53; P ¼ 0.006), and time-toprogression under first-line chemotherapy p6 months (HR, 1.97; 95% CI, 1.39 -2.80; Po0.0001). A prognostic index was constructed dividing patients into low-(no risk factor), intermediate-(one to two risk factors), or high-(three to five risk factors) risk groups, and median survival times for each group were 12.7 months, 7.1 months, and 3.3 months, respectively (Po0.001). In the absence of data deriving from randomised trials, this analysis suggests that some easily available clinical factors may help to select patients with advanced gastric cancer who could derive more benefit from second-line chemotherapy.

show abstract

Section: Second-line Chemotherapy In Metastatic Gastric Cancer V Catamentioning

confidence: 98%

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?

et al. 2008

View full text Add to dashboard Cite

show abstract

“…This treatment results in a complete response in the majority of women; however, most responding patients eventually relapse with disease that becomes resistant not only to platinum compounds, but also to a wide range of other chemotherapeutic agents (Salzberg et al, 2005). The prognosis for women with relapsed ovarian cancer remains poor with a 5-year survival of 25% (Colombo et al, 2006). A greater understanding of the mechanisms underlying drug resistance could lead to measures to overcome it and improve survival.…”

mentioning

confidence: 99%

Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy

et al. 2007

View full text Add to dashboard Cite

Despite high tumour response rates to platinum-based chemotherapy in ovarian cancer survival is poor due to the emergence of drug resistance. Mechanistic studies in clinical material have been hampered by the unavailability of sensitive methods to detect the critical drug-induced effects in individual cells. A modification of the single cell gel electrophoresis (comet) assay allows the sensitive detection of DNA interstrand crosslinking in both tumour and normal cells derived directly from clinical material. Tumour cells isolated from 50 ovarian cancer patients were treated ex vivo with 100 mM cisplatin for 1 h and crosslink formation and repair (unhooking) measured. No significant difference in the peak level of crosslinking in tumour cells was observed between patients who were either newly diagnosed or previously treated with platinum-based therapy, or between tumour and mesothelial cells from an individual patient. This indicates no difference in cellular mechanisms such as drug transport or detoxification. In contrast, the percentage repair (unhooking) of DNA interstrand crosslinks was much greater in the group of treated patients. At 24 h in the 36 newly diagnosed patient tumour samples, only one gave 450% repair and 23 gave o10% repair; however, 19 out of 22 treated patient samples gave 410% repair and 14 showed 450% repair. The estimated median difference (newly diagnosed minus treated) was À52 (95% CI À67 to À28), and the P-value from a Mann -Whitney test was o0.001. In eight patients, it was possible to obtain tumour samples prior to any chemotherapy, and also on relapse or at interval debulking surgery following platinum-based chemotherapy. In these patients, the mean % repair prior to therapy was 2.85 rising to 71.23 following treatment. These data demonstrate increased repair of DNA interstrand crosslinks in ovarian tumour cells following platinum therapy which may contribute to clinical acquired resistance.

show abstract

“…Symptoms of ovarian cancer are nonspecific, such as bloating and constipation, and are usually not evident until late stages of the disease, when 75% of cases are diagnosed (2,3). As early diagnosis remains a challenge, effective treatment strategies are needed to manage the disease.…”

Section: Introductionmentioning

confidence: 99%

Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer

Souza

Zahedi

Moriyama

et al. 2010

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Ovarian cancer is known as the silent killer for being asymptomatic until late stages. Current first-line treatment consists of debulking surgery followed by i.v. chemotherapeutics administered intermittently, which leads to insufficient drug concentrations at tumor sites, accelerated tumor proliferation rates, and drug resistance, resulting in an overall median survival of only 2 to 4 years. For these reasons, more effective treatment strategies must be developed. We have investigated a localized, continuous chemotherapy approach in tumor models of human and murine ovarian cancers using the antineoplastic agent docetaxel. We show here that continuous docetaxel therapy is considerably more efficacious than intermittent therapy, resulting in a greater decrease in tumor burden and ascites fluid accumulation. Immunohistochemical analyses show that continuous chemotherapy abrogates tumor cell proliferation and angiogenesis to the tumor microenvironment, leading to greater tumor cell death than intermittent docetaxel therapy. Overall, our results show greater therapeutic advantages of continuous over intermittent chemotherapy in the treatment of ovarian cancer.

show abstract

Ovarian cancer

Cited by 200 publications

References 140 publications

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?

Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy

Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer

Contact Info

Product

Resources

About